Sleep phenotype characterization of peripheral and central mouse models of myotonic dystrophy

Sakai, Noriaki; Sato, Masaharu; Charizanis, Konstantinos; Lee, K.; Swanson, Maurice S.; Nishino, Seiji

doi:10.1016/j.sleep.2013.11.528

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 Although the associations among CSF orexin levels, short MSL, and SOREMPs are unclear, the presence of REM sleep-related abnormalities in 4 out of 7 patients, which was confirmed by detailed PSG or MSLT findings, is interesting. Studies on the mouse model of DM1 have already demonstrated the role of MBNL2 in REM sleep dysregulation, 1 , 26 and the relationship between the underlying mechanism and orexin nervous system should also be investigated.…”

Section: Discussionmentioning

confidence: 99%

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness

Omori

Kanbayashi

Imanishi

et al. 2018

NDT

View full text Add to dashboard Cite

PurposeMyotonic dystrophy type 1 (DM1) is often characterized by excessive daytime sleepiness (EDS) and sleep-onset rapid eye movement periods caused by muscleblind-like protein 2. The EDS tends to persist even after treatment of sleep apnea. We measured the cerebrospinal fluid (CSF) orexin levels in DM1 patients with EDS and compared the clinical characteristics with narcolepsy type 1 and idiopathic hypersomnia (IHS) patients.Patients and methodsWe measured the CSF orexin levels in 17 DM1 patients with EDS and evaluated subjective sleepiness using the Epworth Sleepiness Scale (ESS), objective sleepiness using mean sleep latency (MSL), and sleep apnea using apnea-hypopnea index (AHI). We compared the ESS scores and MSL between decreased (≤200 pg/mL) and normal (>200 pg/mL) CSF orexin group in DM1 patients. Furthermore, we compared the CSF orexin levels, ESS scores, MSL, and AHI among patients with DM1, narcolepsy type 1 (n=46), and IHS (n=30).ResultsSeven DM1 patients showed decreased CSF orexin levels. There were significant differences in the ESS scores and MSL between decreased and normal CSF orexin groups in DM1 patients. The ESS scores showed no significant difference among patients with DM1, narcolepsy type 1, and IHS. The MSL in DM1 and IHS patients were significantly higher than narcolepsy type 1 patients (p=0.01, p<0.001). The AHI in DM1 patients was significantly higher than narcolepsy type 1 patients (p=0.042) and was insignificantly different from IHS patients. The CSF orexin levels in DM1 patients were significantly lower than IHS patients and higher than narcolepsy type 1 patients (p<0.001, p<0.001).ConclusionThe CSF orexin levels of DM1 patients moderately decreased compared to those of IHS patients as the control group. However, the EDS of DM1 patients may not be explained by only orexin deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%